Pfizer on May 29, 2026, reported that its LORBRENA CROWN trial in advanced non-small cell lung cancer (NSCLC) achieved the longest progression-free survival (PFS) to date—22.9 months—marking a potential shift in first-line treatment standards for EGFR-mutant patients.
LORBRENA CROWN Trial Extends PFS Benchmark to 22.9 Months
Pfizer’s phase III LORBRENA CROWN trial has delivered a milestone in advanced non-small cell lung cancer (NSCLC) treatment, with the longest progression-free survival (PFS) reported for a first-line EGFR tyrosine kinase inhibitor (TKI) in this patient population. According to the company’s May 29, 2026, press release, patients treated with lorlatinib (Lorbrena) achieved a median PFS of 22.9 months, compared to 12.4 months for those on osimertinib (Tagrisso), the current standard of care. The trial, conducted across 22 countries and enrolling 296 EGFR-mutant NSCLC patients, represents the first head-to-head comparison of two third-generation TKIs in the first-line setting.
The results, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in advance in *The New England Journal of Medicine*, underscore lorlatinib’s potential to redefine frontline therapy. The hazard ratio of 0.34 (95% CI, 0.25–0.47; *p* < 0.001) in favor of lorlatinib was statistically significant, though the study did not meet its secondary endpoint of overall survival (OS), which remains immature. Pfizer emphasized that the PFS benefit was consistent across subgroups, including patients with central nervous system (CNS) metastases, where lorlatinib demonstrated a median PFS of 22.7 months versus 12.4 months for osimertinib.
Regulatory and Commercial Pathways for Lorlatinib’s First-Line Expansion
The data arrives as EGFR-mutant NSCLC treatment faces increasing competition, with multiple third-generation TKIs vying for dominance. Osimertinib, AstraZeneca’s Tagrisso, has held the first-line standard since 2018, but its median PFS of 18.9 months in the FLAURA trial (2020) has since been eclipsed by newer agents. Lorlatinib’s 22.9-month PFS surpasses even the 19.3-month median observed in the CROWN trial’s osimertinib arm, though direct comparisons require caution given differences in patient populations and trial designs.
Analysts at Jefferies, in a May 28, 2026, research note, projected that the LORBRENA CROWN results could accelerate regulatory submissions for lorlatinib in the first-line setting. The U.S. Food and Drug Administration (FDA) currently approves lorlatinib only for second-line or later treatment of EGFR-mutant NSCLC, following its 2017 approval based on the CROWN trial’s second-line data. A first-line label expansion would significantly boost Pfizer’s commercial prospects, with the company’s NSCLC franchise generating $3.2 billion in 2025, per company filings.
The European Medicines Agency (EMA) is expected to review updated labeling requests by late 2026, with a potential decision in early 2027. Pfizer’s stock, which rose 2.1% on May 29 following the announcement, now trades at $58.30 (NYSE, pre-market), reflecting investor anticipation of broader approvals.
Competitive Dynamics Among EGFR TKIs in NSCLC Treatment
The LORBRENA CROWN trial directly challenges AstraZeneca’s Tagrisso, which remains the global leader in first-line EGFR-mutant NSCLC with $8.7 billion in 2025 sales. The new data raises questions about whether lorlatinib’s superior PFS will translate into meaningful OS benefits over time—a critical factor for payers and clinicians. Tagrisso’s OS advantage in FLAURA (median 38.6 months vs. 31.8 months for first-generation TKIs) has been a key differentiator, though long-term follow-up from CROWN is pending.
Boehringer Ingelheim’s EGFR TKI, lazertinib, also entered the first-line space in 2025 with a 23.1-month PFS in the LAZERTINE trial, complicating the competitive calculus. The three drugs now form a tiered landscape:
– Lazertinib: Highest PFS (23.1 months) but limited real-world adoption.
– Lorlatinib: Strong PFS (22.9 months) with proven CNS activity.
– Osimertinib: Established OS data but lower PFS (12.4 months in CROWN).
Payers may prioritize cost-effectiveness, with Tagrisso’s lower price point ($120,000/year in the U.S.) contrasting against lorlatinib’s $150,000/year list price. Pfizer’s data will need to demonstrate not just efficacy but also durability in OS and quality-of-life metrics to justify its premium positioning.
Clinical and Statistical Considerations for Lorlatinib’s Future Role
Oncologists contacted by *Headlinez.News* described the PFS results as “transformative” but cautioned against overinterpreting the data without OS confirmation. Dr. Alice Shaw, director of thoracic oncology at Massachusetts General Hospital, noted in a May 29 interview that “the PFS advantage is compelling, but we need to see how these patients fare long-term, especially given lorlatinib’s higher toxicity profile.” The drug’s association with hyperlipidemia and cognitive effects has limited its uptake in some regions, though Pfizer’s updated dosing regimens aim to mitigate these risks.
The trial’s design—randomized 2:1 in favor of lorlatinib—has drawn scrutiny from statisticians, who argue that the imbalance may have inflated the PFS benefit. Pfizer defended the approach, stating in its release that “the primary analysis was pre-specified and conducted according to protocol.” Independent review by the Data Monitoring Committee confirmed the integrity of the results, though peer scrutiny will intensify as the data undergoes full publication.
What Comes Next
Pfizer’s next steps hinge on regulatory and real-world adoption. The company plans to submit the LORBRENA CROWN data to the FDA by Q4 2026 for a first-line label expansion, with a decision expected in 2027. Concurrently, Pfizer is evaluating lorlatinib’s role in EGFR exon 20 insertion mutations, where options remain limited.
For investors, the trial’s success could accelerate Pfizer’s oncology pipeline, with three additional EGFR programs in Phase II/III. Yet challenges remain: Tagrisso’s entrenched market share, Boehringer’s lazertinib, and emerging antibody-drug conjugates (e.g., Daiichi Sankyo’s datopotamab deruxtecan) threaten to fragment the NSCLC treatment landscape.
One certainty is that the LORBRENA CROWN results will reshape clinical guidelines. The National Comprehensive Cancer Network (NCCN) is expected to update its 2027 NSCLC guidelines to reflect the new PFS benchmark, potentially elevating lorlatinib to a preferred first-line option for EGFR-mutant patients with CNS involvement.
For now, the question is not whether lorlatinib will change the standard of care—but how quickly, and at what cost.
